Evaluation of Slit2 in Systemic Lupus Erythematosus and Systemic Sclerosis Patients
1 other identifier
observational
85
0 countries
N/A
Brief Summary
1.Assessment of slit2 level in SLE patients and its correlation with disease activity. 2-Assessment of slit2 level in SSC patients and its correlation with disease activity
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2021
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 7, 2021
CompletedFirst Posted
Study publicly available on registry
November 3, 2021
CompletedStudy Start
First participant enrolled
December 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2023
CompletedNovember 3, 2021
October 1, 2021
1 year
October 7, 2021
October 22, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
measure the level of slit2 by ELISA in SLE patients
determining level of Slit2 in patients with SLE and define its correlation with disease activity
baseline
Secondary Outcomes (1)
measure the level of slit2 by ELISA in SSC patients
baseline
Interventions
1.Assessment of slit2 level in SLE patients and its correlation with disease activity. 2-Assessment of slit2 level in SSC patients and its correlation with disease activity
Eligibility Criteria
1. Adult SLE Patients 2. Adult SSC patients 3. Adult healthy control
You may qualify if:
- Adult SLE Patients who fulfilled the 2019 EULAR/ACR Classification criteria for Systemic Lupus Erythematosus .
- Adult SSC patients who fulfilled the 2013 EULAR / ACR for SSC
You may not qualify if:
- Individuals with other autoimmune diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident doctor in Rhematology and rehabilitation department
Study Record Dates
First Submitted
October 7, 2021
First Posted
November 3, 2021
Study Start
December 1, 2021
Primary Completion
December 1, 2022
Study Completion
February 1, 2023
Last Updated
November 3, 2021
Record last verified: 2021-10